This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic  Social Bookmarking   What's this?

Siam Oottamasathien, MD; E. David Crawford, MD

Arch Intern Med. 2003;163:661-663.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

ROUTINE SCREENING for prostate cancer remains a controversial topic. Prostate cancer is the most common cause of cancer of men in the United States and caused more than 30 000 deaths in 1999. It involves a wide pathophysiologic spectrum, from indolent disease to rapid growth and metastasis. A continued increase in frequency of prostate cancer is expected as the baby boom generation reaches the higher-risk age range for the disease. The main approaches to manage the disease include prevention, early detection (screening) and treatment, and effective treatment of advanced and/or metastatic disease. Currently, prostate-specific antigen (PSA) is the most important tumor marker for the detection, staging, and monitoring of men with prostate cancer.¹

Wang and colleagues² purified and characterized PSA in 1979, a year before it was first detected in serum.^3-4 Prostate-specific antigen is a 33-kd protein produced and secreted primarily by the prostatic . . . [Full Text of this Article]

From the Division of Urology, University of Colorado Health Sciences Center, Denver. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

An Argument Against Routine Prostate Cancer Screening
Richard M. Hoffman
Arch Intern Med. 2003;163(6):663-665.
EXTRACT | FULL TEXT  

Rebuttal by Drs Oottamasathien and Crawford
Siam Oottamasathien and E. David Crawford
Arch Intern Med. 2003;163(6):665-666.
EXTRACT | FULL TEXT  

Rebuttal by Dr Hoffman
Richard M. Hoffman
Arch Intern Med. 2003;163(6):666.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?
Rodeheffer
J Am Coll Cardiol 2004;44:740-749.
ABSTRACT | FULL TEXT